TRANSPOD
25.8.2020 13:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading hyperloop system (the TransPod system ) to disrupt and redefine commercial transportation, today announced it has signed a memorandum of understanding (MOU) with the Government of Alberta in Canada to support the development of safe, high-speed transportation in Alberta, based on the 1000 km/h TransPod vehicle. The MOU facilitates the process of attracting private investment to the province, in order to build a multi-billion-dollar infrastructure project. The project is estimated to create up to 38,000 jobs over 10 years, diversify Alberta’s economy, improve the efficient movement of people and goods, and reduce Alberta’s carbon emissions by up to 300,000 tonnes per year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005001/en/
The MOU will see Alberta Transportation:
- Support TransPod undertaking further study on the feasibility of developing its technology in Alberta
- Share available transportation data as appropriate that may assist TransPod in assessing the feasibility of its technology
- Work with TransPod officials to identify suitable land that can safely accommodate a test track
- Participate in discussions with potential large institutional investors where suitable
No financial commitments or endorsements have been made by Alberta Transportation regarding the TransPod project.
The phases of the Alberta TransPod project are as follows:
- Short-term: feasibility study (2020-2022)
- Short-term: research and development phase (2020-2024)
- Medium-term: test track construction and high-speed tests (2022-2027)
- Long-term: construction of a full inter-city line between Edmonton and Calgary (to begin in 2025)
“Alberta’s government is supporting new and exciting opportunities for job creation and innovation,” said Ric McIver, Alberta Minister of Transportation. “By supporting TransPod’s feasibility study, Alberta Transportation will provide important information contributing to the research, development, testing, and construction of a full inter-city TransPod line between Edmonton and Calgary. We look forward to seeing this work put Alberta on the forefront of the movement of goods and people.”
The TransPod system is being developed to carry passengers and cargo between cities at over 1000 km/h. Fossil-fuel-free and fully electric, it is a new generation of ultra-high-speed ground transportation being developed for construction around the world. It is built on a proprietary and innovative design that leverages aerospace engineering and is bolstered by a global network of engineering partners. The TransPod vehicle’s top speed is faster than a jet, and it travels at ground level in a protected guideway that is immune to weather. With the convenience of a subway that departs every few minutes, TransPod will avoid airline flight diversions, travel faster than a jet, and three times as fast as a high-speed train.
The TransPod vehicle’s innovative and cost-efficient design is a new leap forward for transportation that is clean, safe, cost-efficient, and comfortable. The company is developing this technology with high safety standards in collaboration with the European Union and United States transportation committees.
“Alberta’s leadership mindset and partnership with TransPod firmly places it at the cutting edge of transportation innovation,” said Sebastien Gendron, co-founder and CEO, TransPod. “Through this strategic agreement that secures the province’s economic future without having to commit any taxpayer dollars, the Government of Alberta is investing in improving growth and quality of life in the region.”
“The space race’s technology led to massive spinoffs worldwide, and our vision for TransPod is to position Canada at a similar level of leadership,” said Ryan Janzen, co-founder and CTO, TransPod. “Future transportation comes from breakthrough innovations — and that’s exactly what we’re doing.”
The TransPod system is being examined by governments and organisations for several projects around the world, and the company is currently in the design and development phase for a testing facility in France. The TransPod vehicle will also be featured in a demonstrator which will be showcased in Canada and France, to unveil new breakthroughs that are part of the 1000km/h TransPod system.
For more information:
TransPod project proposal to the Government of Alberta
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading hyperloop system (the TransPod System ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada.
For more information, visit https://transpod.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
